News | Magnetic Resonance Imaging (MRI) | November 13, 2019

Investigators use powerful imaging technology to reveal that a potential MRI marker of brain inflammation is common among patients with early MS and may be a sign of gray matter injury

An image on Brigham and Women's Hospital's 7T MRI system

November 13, 2019 — Increased immune system activity along the surface of the brain, or meningeal inflammation, may be important for understanding how multiple sclerosis (MS) progresses from the most common and earliest form of the disease known as relapsing remitting MS (RRMS) to a secondary progressive form. The meninges are a thin, protective tissue that covers the brain and spinal cord. One proposed way to more easily see evidence of inflammation at the meninges is by finding leptomeningeal enhancement (LME) on magnetic resonance imaging (MRI) scans. This can appear early in the course of the disease and increases as the disease progresses, yet the most commonly available MRI technology — 3 Tesla (3T) — gives a limited view of this proposed marker. Investigators from Brigham and Women's Hospital have completed a new study using 7 Tesla (7T) MRI — a far more powerful imaging technology — to further examine LME in MS patients. With this new powerful tool, they have found that this proposed marker of brain inflammation in MS patients is more common than previously reported and is tied to lesions in the gray matter regions of the brain. The team's findings are published in the Multiple Sclerosis Journal.

"The 7T MRI scanner affords us new ways of viewing areas of damage in neurologic diseases such as MS that were not well seen using 3T MRI; it's capturing nuances that we would otherwise miss," said corresponding author Jonathan Zurawski, M.D., a neurologist at the Brigham. "The 7T scanner reveals markers or signatures that were poorly characterized or overlooked and may allow us to better understand the disease process and ultimately better treat MS patients. As a clinician, I often hear from patients that they feel worse, even though the MRI may appear stable. I've always thought that there is probably more to the story of that patient; 7T MRI is helping us fill in those details."

The Brigham's 7T MRI unit arrived at the hospital in 2017 and became the second in the country to be approved for clinical use. Since that time, it has been fully integrated into the MRI program at the Brigham. In addition to providing cutting-edge patient care, Brigham investigators are using the 7T to advance research and discovery.

To conduct their study, Zurawski and colleagues enrolled 30 participants with RRMS and 15 heathy control subjects. All participants underwent detailed 7T MRI scans to look for signs of LME and gray matter lesions.

The team found that two-thirds (20/30) of MS subjects had LME compared to only one of the 15 healthy people (6.7 percent), a tenfold increase. (Previous studies of patients with progressive MS using 3T MRI found signs of LME in only 20 to 50 percent of subjects.) MS patients with LME also had a four-to-five-fold increase in cortical lesions and thalamic lesions, telltale signs of gray matter injury seen in MS. Interestingly, these signs were independent of white matter lesions, which are the traditional marker of MS.

The team chose to study patients with RRMS to help address a gap in the current understanding of the disease. They note that their study was limited by its small sample size. While they cannot yet address how treatment of LME may affect disease progression, and whether their findings may apply to patients with the progressive form of the disease, plans are underway to continue following the patients in this study over time to see how LME and gray matter lesions may change over months and years. The team has also expanded the study's size to include more patients in the future.

"Gray matter injury is an important part of MS, which may be a key factor leading to disease progression," said Zurawski. "Our hope is that by finding new markers of this progression, it opens up the opportunity for developing treatments that can prevent progression before lesions become widespread."

For more information: brighamandwomens.org


Related Content

News | ACR

December 8, 2022 — The American College of Radiology (ACR) Board of Chancellors (BOC) named three Gold Medalists, one ...

Time December 08, 2022
arrow
News | Ultrasound Imaging

December 8, 2022 — Butterfly Network, Inc., a digital health company transforming care with handheld, whole-body ...

Time December 08, 2022
arrow
News | Digital Radiography (DR)

December 7, 2022 — Carestream Health exhibited its expanding portfolio of new products and enhanced solutions at the ...

Time December 07, 2022
arrow
News | Coronavirus (COVID-19)

December 7, 2022 — A research team at the Technical University of Munich (TUM) has, for the first time, produced dark ...

Time December 07, 2022
arrow
News | Coronavirus (COVID-19)

December 7, 2022 — Gross anatomy reveals three-dimensional shapes of pathology at a large scale. Histology, in contrast ...

Time December 07, 2022
arrow
News | Contrast Media

December 5, 2022 — Bracco Diagnostics Inc., a U.S. subsidiary of Bracco Imaging S.p.A., has announced results from a ...

Time December 05, 2022
arrow
News | RSNA

December 5, 2022 — With AI becoming an integral part of clinical radiology workflows, the data used to develop AI ...

Time December 05, 2022
arrow
News | Radiology Business

December 5, 2022 — IMV, part of Science and Medicine Group, the leading market research and business intelligence ...

Time December 05, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a recap of what ITN viewers found most interesting during the month of November: 1. Top 10 Predictions for ...

Time December 05, 2022
arrow
News | Prostate Cancer

December 2, 2022 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time December 02, 2022
arrow
Subscribe Now